Trial Profile

A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab-deruxtecan (Primary)
Indications Cancer
Focus Adverse reactions; Registrational
Sponsors Daiichi Sankyo Biotech

Most Recent Events

15 Oct 2025 Planned End Date changed from 3 Aug 2026 to 17 Jan 2028.
01 May 2024 Status changed from not yet recruiting to recruiting.
27 Feb 2024 Planned initiation date changed from 31 Dec 2023 to 31 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com